Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer,S. D. Anker,J. Butler,G. Filippatos,S. J. Pocock,P. Carson,James L. Januzzi,S. Verma,H. Tsutsui,M. Brueckmann,W. Jamal,K. Kimura,J. Schnee,C. Zeller,D. Cotton,Edimar Alcides Bocchi,M. Böhm,Dong-Ju Choi,V. Chopra,E. Chuquiure,N. Giannetti,S. Janssens,J. Zhang,J. R. Gonzalez Juanatey,Sanjay Kaul,H. P. Brunner-La Rocca,Béla Merkely,Stephen J. Nicholls,Sergio V. Perrone,I. Pina,P. Ponikowski,N. Sattar,Michele Senni,M. F. Seronde,J. Spinar,Iain B. Squire,S. Taddei,Christoph Wanner,F. Zannad +38 more
TLDR
Those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.Abstract:
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More eviden...read more
Citations
More filters
Journal ArticleDOI
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Theresa McDonagh,Marco Metra,Marianna Adamo,Roy S. Gardner,Andreas Baumbach,Michael Böhm,Haran Burri,Javed Butler,Jelena Čelutkienė,Ovidiu Chioncel,John G F Cleland,A J S Coats,Maria G Crespo-Leiro,Dimitrios Farmakis,Martine Gilard,Stephane Heymans,Arno W. Hoes,Tiny Jaarsma,Ewa A. Jankowska,Mitja Lainscak,Carolyn S.P. Lam,Alexander R. Lyon,John J.V. McMurray,Alexandre Mebazaa,Richard Mindham,Claudio Muneretto,Massimo F Piepoli,Susanna Price,Giuseppe M.C. Rosano,Frank Ruschitzka,Anne Kathrine Skibelund +30 more
Journal ArticleDOI
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren,François Mach,Yvo M. Smulders,David Carballo,Konstantinos C. Koskinas,Maria Bäck,Athanase Benetos,Alessandro Biffi,José-Manuel Boavida,Davide Capodanno,Bernard Cosyns,Carolyn Crawford,Constantinos H. Davos,Ileana Desormais,Emanuele Di Angelantonio,Oscar H. Franco,Sigrun Halvorsen,FD Richard Hobbs,Monika Hollander,Ewa A. Jankowska,Matthias Michal,Simona Sacco,Naveed Sattar,Lale Tokgozoglu,Serena Tonstad,Konstantinos P Tsioufis,Ineke van Dis,Isabelle C. Van Gelder,Christoph Wanner,Bryan Williams,Guy De Backer,Vera Regitz-Zagrosek,Anne Hege Aamodt,Magdy Abdelhamid,Victor Aboyans,Christian Albus,Riccardo Asteggiano,Magnus Bäck,Michael A. Borger,Carlos Brotons,Jelena Čelutkienė,Renata Cifkova,Maja Čikeš,Francesco Cosentino,Nikolaos Dagres,Tine De Backer,Dirk De Bacquer,Victoria Delgado,Hester Den Ruijter,Paul Dendale,Heinz Drexel,Volkmar Falk,Laurent Fauchier,Brian A. Ference,Jean Ferrières,Marc Ferrini,Miles Fisher,Danilo Fliser,Zlatko Fras,Dan Gaita,Simona Giampaoli,Stephan Gielen,Ian D. Graham,Catriona Jennings,Torben Jørgensen,Alexandra Kautzky-Willer,Maryam Kavousi,Wolfgang Koenig,Aleksandra Konradi,Dipak Kotecha,Ulf Landmesser,Madalena Lettino,Basil S. Lewis,Aleš Linhart,Maja-Lisa Løchen,Konstantinos Makrilakis,Giuseppe Mancia,Pedro Marques-Vidal,John W. McEvoy,Paul McGreavy,Béla Merkely,Lis Neubeck,Jens Cosedis Nielsen,Joep Perk,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Nana Pogosova,Eva Prescott,Kausik K. Ray,Zeljko Reiner,Dimitrios J. Richter,Lars Rydén,Evgeny Shlyakhto,Marta Sitges,Miguel Sousa-Uva,Isabella Sudano,Monica Tiberi,Rhian M. Touyz,Andrea Ungar,W. M. Monique Verschuren,Olov Wiklund,David A. Wood,José Luis Zamorano,Carolyn A Crawford,Oscar H Franco Duran +105 more
Journal ArticleDOI
Empagliflozin in heart failure with a preserved ejection fraction
Stefan D. Anker,Javed Butler,Gerasimos Filippatos,João Pedro Ferreira,Edimar Bocchi,Michael Böhm,Hans-Peter Brunner-La Rocca,Dong-Ju Choi,Vijay K. Chopra,Eduardo Chuquiure-Valenzuela,Nadia Giannetti,Juan Esteban Gomez-Mesa,Stefan Janssens,James L. Januzzi,Jose R Gonzalez-Juanatey,Bela Merkely,Stephen J. Nicholls,Sergio V. Perrone,Ileana L. Piña,Piotr Ponikowski,Michele Senni,David K.L. Sim,Jindrich Spinar,Iain Squire,Stefano Taddei,Hiroyuki Tsutsui,Subodh Verma,Dragos Vinereanu,Jian Zhang,Peter E. Carson,Carolyn Su Ping Lam,Nikolaus Marx,Cordula Zeller,Naveed Sattar,Waheed Jamal,Sven Schnaidt,Janet Schnee,Martina Brueckmann,Stuart J. Pocock,Faiez Zannad,Milton Packer,EMPEROR-Preserved Trial Investigators +41 more
TL;DR: In this paper, a double-blind trial was conducted to evaluate the effect of empagliflozin on the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
Journal ArticleDOI
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Paul A. Heidenreich,Biykem Bozkurt,David Aguilar,Larry A. Allen,Joni J. Byun,Monica Colvin,Anita Deswal,Mark H. Drazner,Shannon M. Dunlay,Linda R. Evers,James C. Fang,Savitri Fedson,Gregg C. Fonarow,Salim S. Hayek,Adrian F. Hernandez,Prateeti Khazanie,Michelle M. Kittleson,Christopher S. Lee,Mark S. Link,Carmelo A. Milano,Lorraine C. Nnacheta,Alexander T. Sandhu,Lynne W. Stevenson,Orly Vardeny,Amanda R. Vest,Clyde W. Yancy +25 more
TL;DR: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" as discussed by the authors provides patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
Journal ArticleDOI
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt,Michael Szarek,P. Gabriel Steg,Christopher P. Cannon,Lawrence A. Leiter,Darren K. McGuire,Julia B. Lewis,Matthew C. Riddle,Adriaan A. Voors,Marco Metra,Lars H. Lund,Michel Komajda,Jeffrey M. Testani,Christopher S. Wilcox,Piotr Ponikowski,Renato D. Lopes,Subodh Verma,Pablo Lapuerta,Bertram Pitt +18 more
TL;DR: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo.
References
More filters
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Journal ArticleDOI
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker,Stephen D. Wiviott,Itamar Raz,KyungAh Im,Erica L. Goodrich,Marc P. Bonaca,Ofri Mosenzon,Eri Toda Kato,Avivit Cahn,Remo H.M. Furtado,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc S. Sabatine +14 more
TL;DR: SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atheroscerotic cardiovascular disease, however, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerosis or a history of heart failure.
Journal ArticleDOI
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
David Fitchett,Silvio E. Inzucchi,Christopher P. Cannon,Darren K. McGuire,Benjamin M. Scirica,Odd Erik Johansen,Steven Sambevski,Stefan Kaspers,Egon Pfarr,Jyothis T. George,Bernard Zinman +10 more
TL;DR: Patients in EMPA-REG OUTCOME demonstrated a broad risk spectrum for cardiovascular events, and reductions in key cardiovascular outcomes and mortality with empagliflozin versus placebo were consistent across the range of cardiovascular risk.
Journal ArticleDOI
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
TL;DR: The EMPEROR‐Reduced trial is well‐positioned to determine if the addition of empagliflozin can add meaningfully to current approaches that have established benefits in the treatment of chronic heart failure with left ventricular systolic dysfunction.
Related Papers (5)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more